Safety of MT-401-OTS in Patients With Relapsed AML or MDS (NCT06552416)
A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID)
🩺 Plain-English Summary (8th-Grade Level)
This study is a Phase 1 multicenter, open-label study evaluating the safety and efficacy of escalating doses of MT-401-OTS in 2 participant populations: 1) Those with intermediate or high-risk AML per 2022 ELN criteria who have evidence of MRD and/or \</= 10% blast following prior induction therapy or at least 4 cycles of nonintensive therapy and 2) those with high- or very-high-risk MDS per 2023 IWG criteria and who have residual disease with \</= 10% blasts following treatment with an HMA-based therapy.
Who can join: Review the eligibility criteria below.
Location: City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
Age range: 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center) — Duarte, California
- Moffitt Cancer Center — Tampa, Florida
- KU Cancer Center — Kansas City, Kansas
📞 Contact the Study Coordinator
Phone: (713) 400-6400
Email: pallison@markertherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia, in Relapse
- Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) — Gilbert, Arizona
- A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies — Charlotte, North Carolina
- Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS — Charlotte, North Carolina
- Venetoclax to Augment Epigenetic Modification and Chemotherapy — Milwaukee, Wisconsin
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) — La Jolla, California
- Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Charlottesville, Virginia
Explore by condition: All Acute Myeloid Leukemia, in Relapse clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.